公开(公告)号：US20240335469A1

公开(公告)日：2024-10-10

申请号：US18204475

申请日：2023-06-01

Applicant: AMNEAL EU, LIMITED

Inventor： Piyush Amrutlal Patel ,  Chiragkumar Girishbhai Siddhapara ,  Aditya Maheshchandra Patel ,  Amarender Raddy Donthisi ,  Srinivas Ramachandra Rao Kone

IPC: A61K33/42 ,  A61K9/00 ,  A61K47/02

CPC classification number: A61K33/42 ,  A61K9/0019 ,  A61K47/02

Abstract: The present invention relates to a ready-to-use injection compositions of potassium phosphates in sodium chloride and methods for preparing the same. The ready-to-use injection compositions contain 15 mmol/250 mL of phosphorus, 22 mEq/250 mL of potassium, equal or less than about 25 mcg/mL of aluminum and exhibit an osmolality value of from about 250 mOsmol/kg to about 450 mOsmol/kg. The ready-to-use injection compositions of the disclosure do not require any further reconstitution step prior to use.

公开(公告)号：US12109285B2

公开(公告)日：2024-10-08

申请号：US15539748

申请日：2014-12-26

Applicant: Colgate-Palmolive Company

Inventor： Baohua Qiao ,  Long Pan ,  Gregory Szewczyk ,  Ravi Subramanyam

IPC: A61K8/27 ,  A61K6/20 ,  A61K6/74 ,  A61K8/24 ,  A61K33/42 ,  A61Q11/00

CPC classification number: A61K8/27 ,  A61K6/20 ,  A61K6/74 ,  A61K8/24 ,  A61K33/42 ,  A61Q11/00 ,  A61K2800/58

Abstract: An oral care composition having a soluble zinc polyphosphate complex made by combining ingredients including an inorganic zinc salt, and a plurality of long chain polyphosphates having 6 or more phosphate polymer units, the relative amount of inorganic zinc salt and long chain polyphosphates providing a phosphorus to zinc mole ratio of at least 6:1. Further provided is a method of treating a subject suffering from dentinal sensitivity applying the oral care composition to the teeth and gums of the subject.

公开(公告)号：US12109233B2

公开(公告)日：2024-10-08

申请号：US16467678

申请日：2016-12-21

Applicant: DR.C MEDICAL MEDICINE CO., LTD.

Inventor： Narumi Okazaki

IPC: A61K33/42 ,  A41D13/11 ,  A61K9/70 ,  A61K33/24 ,  A61K33/242 ,  A61K33/243 ,  A61K33/38

CPC classification number: A61K33/42 ,  A41D13/11 ,  A61K9/70 ,  A61K33/24 ,  A61K33/242 ,  A61K33/243 ,  A61K33/38

Abstract: A problem to be solved by the present invention is to provide a pharmaceutical preparation to be administered to the intranasal mucosa, and in order to solve such a problem, the present invention provides a pharmaceutical preparation to be administered to the intranasal mucosa, in which the pharmaceutical preparation includes a composite particle containing one or more titanium oxide particles, one or more metal particles, and one or more calcium phosphate particles.

公开(公告)号：US20240293451A1

公开(公告)日：2024-09-05

申请号：US18659445

申请日：2024-05-09

Applicant: TOHOKU UNIVERSITY

Inventor： Osamu SUZUKI ,  Ryo HAMAI ,  Yukari SHIWAKU ,  Kaori TSUCHIYA ,  Shinki KOUYAMA

IPC: A61K33/42 ,  A61K47/42 ,  A61P9/00 ,  A61P19/08

CPC classification number: A61K33/42 ,  A61K47/42 ,  A61P9/00 ,  A61P19/08

Abstract: An angiogenesis material, a bone-regeneration-promoting material, a method for producing an angiogenesis material and a method for producing a bone-regeneration-promoting material which particularly improve angiogenesis capacity, angiogenesis capacity and osteogenesis capacity, are particularly effective for bone regeneration and are expected to be applied not only to bone regeneration but also to regeneration of various tissues in which angiogenesis is required are provided. These are an angiogenesis material containing a composite of a metal-octacalcium phosphate-containing material containing octacalcium phosphate and a metal element and a bioabsorbable polymer, a bone-regeneration-promoting material using the same, and production methods thereof.

公开(公告)号：US12059465B2

公开(公告)日：2024-08-13

申请号：US15823151

申请日：2017-11-27

Applicant: Mars, Incorporated

Inventor： Edward Russell Cox ,  Douglas Joseph Dobrozsi ,  Thomas Edward Huetter ,  Allan John Lepine ,  Susan Ruth Beyer

IPC: A23K20/24 ,  A23K20/20 ,  A23K40/30 ,  A23K50/42 ,  A23K50/45 ,  A61K31/28 ,  A61K31/30 ,  A61K31/315 ,  A61K31/32 ,  A61K33/24 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K33/42 ,  A61K45/06

CPC classification number: A61K45/06 ,  A23K20/30 ,  A23K40/30 ,  A23K50/42 ,  A23K50/45 ,  A61K31/28 ,  A61K31/30 ,  A61K31/315 ,  A61K31/32 ,  A61K33/24 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K33/42 ,  A61K31/28 ,  A61K2300/00 ,  A61K31/30 ,  A61K2300/00 ,  A61K31/315 ,  A61K2300/00 ,  A61K31/32 ,  A61K2300/00 ,  A61K33/24 ,  A61K2300/00 ,  A61K33/30 ,  A61K2300/00 ,  A61K33/32 ,  A61K2300/00 ,  A61K33/34 ,  A61K2300/00 ,  A61K33/42 ,  A61K2300/00

Abstract: Edible compositions are provided and comprise a soluble mineral component and/or a phosphate component in amounts effective for use as an oral medicament. The soluble mineral component comprises one or more minerals selected from the group consisting of zinc, manganese, tin, copper, and mixtures thereof. The edible compositions are advantageously companion animal chews, treats or supplements. Further disclosed are methods of making the chews, treats or supplements as are methods of treating conditions of the oral cavity.

公开(公告)号：US12042514B2

公开(公告)日：2024-07-23

申请号：US18122478

申请日：2023-03-16

Applicant: Tygrus, LLC

Inventor： Paul Bundschuh ,  Lawrence Carlson ,  Shawn Dolan ,  Andrew M. Yaksic

IPC: A61K33/42 ,  A61K9/00 ,  A61K31/137 ,  A61K31/198 ,  A61K31/215 ,  A61K31/4045 ,  A61K31/405 ,  A61K31/4704 ,  A61K31/513 ,  A61K31/569 ,  A61K31/573 ,  A61K31/58 ,  A61K31/616 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7076 ,  A61K33/00 ,  A61K33/04 ,  A61K33/20 ,  A61K33/40 ,  A61K45/06 ,  A61P31/04 ,  A61P31/10 ,  A61P31/14 ,  A61P31/16

CPC classification number: A61K33/42 ,  A61K9/0078 ,  A61K31/137 ,  A61K31/198 ,  A61K31/215 ,  A61K31/4045 ,  A61K31/405 ,  A61K31/4704 ,  A61K31/513 ,  A61K31/569 ,  A61K31/573 ,  A61K31/58 ,  A61K31/616 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7076 ,  A61K33/00 ,  A61K33/04 ,  A61K33/20 ,  A61K33/40 ,  A61K45/06 ,  A61P31/04 ,  A61P31/10 ,  A61P31/14 ,  A61P31/16

Abstract: Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.

公开(公告)号：US12023317B2

公开(公告)日：2024-07-02

申请号：US17687682

申请日：2022-03-07

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Jin Chul Kim ,  Jung Yeob Ham ,  Tae Jung Kim ,  Dorjsembe Banzragch ,  Ha Neul Ju ,  Hyung Seok Yu

IPC: A61K31/365 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K31/07 ,  A61K31/197 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/714 ,  A61K33/00 ,  A61K33/06 ,  A61K33/10 ,  A61K33/26 ,  A61K33/30 ,  A61K33/42 ,  A61K36/73 ,  A61K47/12 ,  A61K47/20 ,  A61P37/06

CPC classification number: A61K31/365 ,  A61K9/0019 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/1623 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/205 ,  A61K9/2059 ,  A61K31/07 ,  A61K31/197 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/714 ,  A61K33/00 ,  A61K33/06 ,  A61K33/10 ,  A61K33/26 ,  A61K33/30 ,  A61K33/42 ,  A61K36/73 ,  A61K47/12 ,  A61K47/20 ,  A61P37/06 ,  A61K2236/331 ,  A61K2236/333

Abstract: Disclosed is a composition for use in preventing, alleviating, or treating psoriasis containing cimicifugolide A as an active ingredient.

公开(公告)号：US11975037B2

公开(公告)日：2024-05-07

申请号：US15549954

申请日：2016-02-05

Applicant: AMOREPACIFIC CORPORATION

Inventor： Su-Hwan Kim ,  Chan-Woong Park ,  Sun Mi Kim ,  Juewon Kim ,  Byung Gyu Kim ,  Wan Gi Kim ,  Sang Jun Lee

IPC: A61K36/258 ,  A23L33/00 ,  A23L33/105 ,  A23L33/15 ,  A23L33/16 ,  A61K31/07 ,  A61K31/122 ,  A61K31/197 ,  A61K31/353 ,  A61K31/355 ,  A61K31/375 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/675 ,  A61K31/704 ,  A61K31/7048 ,  A61K33/00 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K33/42 ,  A61K35/32 ,  A61K36/232 ,  A61K36/40 ,  A61K36/534 ,  A61K36/54 ,  A61K36/64 ,  A61K36/725 ,  A61K36/79

CPC classification number: A61K36/258 ,  A23L33/105 ,  A23L33/15 ,  A23L33/16 ,  A23L33/30 ,  A61K31/07 ,  A61K31/122 ,  A61K31/197 ,  A61K31/353 ,  A61K31/355 ,  A61K31/375 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/675 ,  A61K31/704 ,  A61K31/7048 ,  A61K33/00 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K33/42 ,  A61K35/32 ,  A61K36/232 ,  A61K36/40 ,  A61K36/534 ,  A61K36/54 ,  A61K36/64 ,  A61K36/725 ,  A61K36/79 ,  A23V2002/00 ,  A61K36/258 ,  A61K2300/00 ,  A61K36/534 ,  A61K2300/00 ,  A61K36/232 ,  A61K2300/00 ,  A61K36/40 ,  A61K2300/00 ,  A61K36/54 ,  A61K2300/00 ,  A61K36/64 ,  A61K2300/00 ,  A61K36/725 ,  A61K2300/00 ,  A61K36/79 ,  A61K2300/00 ,  A23V2002/00 ,  A23V2200/322 ,  A23V2250/2124

Abstract: The present specification relates to a composition for preventing, alleviating or treating burnout syndrome, containing a natural extract as an active ingredient. According to one aspect of the present invention, the composition contains a ginseng fruit extract, and thus is useful for preventing, treating and alleviating burnout syndrome. In addition, according to one aspect of the present invention, the composition further contains ginseng fruit and one or more selected from the group consisting of red ginseng, Angelica gigas, Cornus officinalis, Cervi parvum corni, and Nigella sativa, so as to maximize the synergistic effect among two or more ingredients, thereby exhibiting excellent effects on the prevention, treatment and alleviation of burnout syndrome. Therefore, there is an advantage of making individuals and society mentally and physically healthy since burnout syndrome can be prevented, treated and alleviated, by using the composition of the present invention.

公开(公告)号：US11930836B2

公开(公告)日：2024-03-19

申请号：US17505781

申请日：2021-10-20

Applicant: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.

Inventor： Nora Schneider ,  Jonas Hauser ,  Sean Deoni ,  Tamas Bartfai

IPC: A23L33/00 ,  A23L33/12 ,  A23L33/15 ,  A23L33/16 ,  A24B15/38 ,  A61K9/00 ,  A61K31/14 ,  A61K31/202 ,  A61K31/519 ,  A61K31/661 ,  A61K31/70 ,  A61K31/714 ,  A61K33/00 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K33/42 ,  A61K45/06 ,  A61P25/28

CPC classification number: A23L33/40 ,  A23L33/12 ,  A23L33/15 ,  A23L33/16 ,  A23L33/30 ,  A24B15/38 ,  A61K9/0095 ,  A61K31/14 ,  A61K31/202 ,  A61K31/519 ,  A61K31/661 ,  A61K31/70 ,  A61K31/714 ,  A61K33/00 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K33/42 ,  A61K45/06 ,  A61P25/28 ,  A23V2002/00 ,  A23V2200/322 ,  A23V2250/1564 ,  A23V2250/1578 ,  A23V2250/1588 ,  A23V2250/1592 ,  A23V2250/161 ,  A23V2250/1618 ,  A23V2250/1642 ,  A23V2250/1846 ,  A23V2250/185 ,  A23V2250/1852 ,  A23V2250/1862 ,  A23V2250/1886 ,  A23V2250/5424 ,  A23V2250/7056 ,  A23V2250/706 ,  A61K33/26 ,  A61K2300/00 ,  A61K33/30 ,  A61K2300/00 ,  A61K33/34 ,  A61K2300/00 ,  A61K33/06 ,  A61K2300/00 ,  A61K33/42 ,  A61K2300/00 ,  A61K31/714 ,  A61K2300/00 ,  A61K31/519 ,  A61K2300/00 ,  A61K31/202 ,  A61K2300/00 ,  A61K31/685 ,  A61K2300/00 ,  A61K31/688 ,  A61K2300/00 ,  A61K31/133 ,  A61K2300/00 ,  A61K31/20 ,  A61K2300/00 ,  A24B15/38 ,  A23V2002/00 ,  A23V2200/322 ,  A23V2250/1578 ,  A23V2250/1588 ,  A23V2250/1592 ,  A23V2250/16 ,  A23V2250/161 ,  A23V2250/1612 ,  A23V2250/1614 ,  A23V2250/1618 ,  A23V2250/1642 ,  A23V2250/1846 ,  A23V2250/1848 ,  A23V2250/185 ,  A23V2250/1852 ,  A23V2250/1862 ,  A23V2250/1868 ,  A23V2250/304 ,  A23V2250/54242 ,  A23V2250/7056 ,  A23V2002/00 ,  A23V2200/322 ,  A23V2250/1592 ,  A23V2002/00 ,  A23V2200/322 ,  A23V2250/1642 ,  A23V2002/00 ,  A23V2200/322 ,  A23V2250/1618 ,  A23V2002/00 ,  A23V2200/322 ,  A23V2250/1578 ,  A23V2002/00 ,  A23V2200/322 ,  A23V2250/1588 ,  A23V2002/00 ,  A23V2200/322 ,  A23V2250/161

Abstract: A synthetic nutritional composition comprising a fatty acid derivative for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

公开(公告)号：US20240074954A1

公开(公告)日：2024-03-07

申请号：US18262945

申请日：2022-01-25

Applicant: MERZ NORTH AMERICA

Inventor： Bartosch NOWAG ,  Roland STRAGIES ,  Thomas HENGL ,  Dean ERICKSON ,  Tim LIGMAN ,  Christopher GROPPI

IPC: A61K8/24 ,  A61K8/02 ,  A61K9/00 ,  A61K33/42 ,  A61K45/06 ,  A61Q19/08 ,  C01B25/32

CPC classification number: A61K8/24 ,  A61K8/025 ,  A61K9/0019 ,  A61K33/42 ,  A61K45/06 ,  A61Q19/08 ,  C01B25/32 ,  A61K2800/91 ,  C01P2004/32 ,  C01P2004/51 ,  C01P2004/61

Abstract: The invention relates to calcium hydroxyapatite particles having been sintered at a certain temperature range and which are not treated at a temperature above this range. Furthermore, the present invention relates to an injectable composition comprising such particles and to uses thereof. Surprisingly, it was found that the particles of the invention are superior over calcium hydroxyapatite particles known in the art with respect to bio-stimulation.